- Peter H Addy
- 3 Hours 48 Minutes
- Audio and Video
- Sep 29, 2020
MDMA-assisted psychotherapy is increasingly in the news as a novel and exciting breakthrough in psychotherapy, and a rapid outpouring of research continues to show promising benefits in treating PTSD, anxiety associated with terminal illness, and social anxiety in autistic adults. But what does this mean for your clients?
Watch international speaker and psychedelics expert Peter H. Addy, Ph.D., LPC, LMHC, and you’ll discover the latest MDMA research and how the FDA is responding to it. You’ll walk away able to translate the implications of this research into clinically relevant information, skills, and strategies that you can apply in your practice right now.
Purchase today, and you’ll learn:
- How MDMA works & how it may assist psychotherapy
- Legal avenues for MDMA-assisted therapy now, & more that may become available soon
- Assessment strategies for recreational ecstasy use
- Evidence-based clinical skills that improve treatment outcomes
- How to navigate the legal & ethical challenges associated with MDMA
Don’t miss this chance to prepare yourself for the future of clinical treatment. Purchase today!
|Manual – MDMA-Assisted Psychotherapy & Ecstasy (2.9 MB)||58 Pages||Available after Purchase|
MDMA vs. Ecstasy: What You Need to Know
- Pharmacology: How MDMA works in the brain & body
- MDMA & ecstasy are different things
- Assessment strategies for ecstasy use
- Risks associated with ecstasy use
The Science Behind MDMA-Assisted Therapy
- Clinical trials: Completed & Ongoing Research
- Social anxiety in autistic adults
- End-of-life anxiety
- Conjoint therapy
- Startle testing
- Contraindications for use
- Limitations of the research & potential risks
Evidence-Based Clinical Skills for Better Treatment
- Non-directive psychotherapy
- Somatic approaches: Before & after
- Therapeutic silence: Letting the client lead
- Case studies: Research participants tell their own stories
Legal & Ethical Considerations
- Changing legal frameworks
- Phase III clinical trials & rescheduling MDMA
- FDA Expanded Access program opportunities
- Ethical concerns
- Access and equity: Who deserves to receive this treatment?
- Informed consent & sexual trauma
Peter H Addy, PhD, LPC, LMHC, has studied psychedelic substances and states and consciousness for 15 years. He earned a PhD in clinical psychology studying transcendence, wholeness, and transformation and conducted one of the earliest studies of the atypical psychedelic plant Salvia divinorum in humans. He continued refining his research and clinical skills at Yale University where he studied Salvia and other atypical psychedelics and co-founded the Yale Psychedelic Science Group. He has completed postdoctoral training in substance use disorder treatment, participated in non-directive harm reduction and integration training at Burning Man, and traveled to Mexico to learn about indigenous use of psychedelic plants among the Mazatec people. He is currently a psychotherapist in private practice in Washington and Oregon.
Dr. Addy has presented internationally on a variety of subjects related to spirituality and transpersonal states, psychedelic science, and research methodology. Participants consistently regarded his talks as informative, accessible, and humorous. He has written numerous scientific articles, book chapters, and popular press articles on typical and atypical psychedelics, substance abuse, and spirituality.
Financial: Peter Addy maintains a private practice. He receives a speaking honorarium from PESI, Inc.
Non-financial: Peter Addy has no relevant non-financial relationship to disclose.